13 results about "Levocarnitine" patented technology

The invention discloses a kind of preparation method of L-carnitine, comprise the steps:Trimethylamine is added in the mixed solution of NaOH, water and organic solvent, R-4-chloro-3-hydroxybutyric acid ethyl ester is slowly dripped under cryogenic conditions, stirring reaction under identical temperature conditions after dropping and finishing;Raise temperature, continue reaction;Hydrochloric acid is dripped into reaction solution and adjusted pH value until reaction solution pH value is neutral, obtain the reaction solution containing L-carnitine;Desalt the reaction solution containing L-carnitine by electrodialysis, distillation and water removal, obtain L-carnitine. The scheme provided by the application is simple to operate, mild condition, and greatly reduces the reaction time simultaneously, is suitable for industrialized production, and by screening appropriate organic solvent and mixing with water to reduce freezing point to lower reaction temperature, suppresses the generation of impurities, thus improves product yield.

Disclosed is a levocarnitine and trimetazidine bilayer tablet. The present disclosure adopts a bilayer structure of the levocarnitine and trimetazidine dihydrochloride, and a contact area between the levocarnitine layer and the air can be greatly reduced by covering one side of a surface of the levocarnitine layer with the trimetazidine dihydrochloride layer, such that the problem of hygroscopicity of the levocarnitine layer can be effectively inhibited, and the effective amount of the drug is increased. Moreover, the preparation process in the present disclosure is easy to operate and suitable for actual production and use, as well as is capable of solving the problem of content uniformity well, and the stability of the bilayer tablet is effectively improved.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The invention discloses a levocarnitine refining method which comprises the following steps: mixing and heating a levocarnitine crude product and a recrystallization solvent until the levocarnitine crude product and the recrystallization solvent are completely dissolved, then cooling and crystallizing, and carrying out suction filtration, washing and drying to obtain high-purity levocarnitine, wherein the recrystallization solvent comprises a first solvent and a second solvent; the first solvent is at least one of tetrahydrofuran, acetone, acetonitrile, n-butyl alcohol, ethyl acetate and N, N-dimethylformamide; the second solvent is at least one of water and ethanol; the mass ratio of the first solvent to the second solvent is 1: (0.2-8). According to the method disclosed by the invention, 4-(trimethyl ammonium) butyl-2-olefine acid inner salt and 4-(trimethyl amino)-2-butenamide impurities with similar structures in the levocarnitine crude product can be effectively removed, the purity of the product reaches 99.5% or above, the product meets the pharmacopoeia standard, and the quality of the product has obvious competitiveness.

The invention provides levocarnitine chewable tablets as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The levocarnitine chewable tablet disclosed by the invention is prepared from levocarnitine, modified hydroxypropyl methyl cellulose, microcrystalline cellulose PH102, sodium carboxymethyl starch, quaternized chitosan, sodium caprate, sulfobutyl ether-beta-cyclodextrin, mannitol, sorbitol, sodium stearyl fumarate and superfine silica powder. The modified hydroxypropyl methyl cellulose is prepared from hydroxypropyl methyl cellulose through citric acid crosslinking and 1, 2-propylene glycol carbonate reaction in sequence, initial release and later slow release of the levocarnitine can be controlled, and long-acting release of the levocarnitine is achieved. The levocarnitine chewable tablet can realize stable release of levocarnitine and maintain stable blood concentration, has palatability and high bioavailability, is especially suitable for patients with dysphagia, and has important clinical value.

The invention provides a preparation and purification method of (S)-3-chloro-2-hydroxypropyl trimethyl ammonium chloride, which comprises the following steps: dissolving trimethyl hydrochloride in methanol to obtain a solution, adding S-epichlorohydrin into the solution for reaction, partially or completely removing a reaction solvent after the reaction is finished, and then adding dichloromethane for pulping to remove impurities. According to the technical scheme, high-temperature distillation treatment is not needed, byproducts are few, especially biquaternary ammonium salt impurities grow slowly, hydrolysis impurities and basic toxic impurities such as S-epichlorohydrin can be effectively removed, and medication safety and effectiveness of the levocarnitine product are guaranteed.

This invention belongs to the field of pharmaceutical formulations, specifically relating to a levocarnitine oral gel and its preparation method. This invention discloses a stable levocarnitine oral gel composition comprising levocarnitine, a gel matrix, an alkali metal salt, and sodium polyacrylate. The stable levocarnitine oral gel disclosed in this invention is easy to swallow, has good medication adherence, does not undergo dehydration and shrinkage during the observation period, has stable product quality, good safety, and is convenient to carry and use; the process is simpler, with high production efficiency and lower risk, making it suitable for large-scale industrial production.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a pharmaceutical composition in the treatment of moderate fatty liver. This invention provides a combination of levocarnitine and trimetazidine, which, through the synergistic effect of levocarnitine and trimetazidine, treats moderate non-alcoholic fatty liver from the perspective of fat and glucose metabolism, thereby achieving its application in the treatment of moderate fatty liver.

The application discloses a method for determining potential genotoxic impurities in levocarnitine by GC-MS, comprising the following steps: preparing a test sample solution: taking 0.2-3g of levocarnitine, accurately weighing, placing in a centrifugal tube, adding 1-2ml of water, shaking to dissolve the sample, adding 5ml of acetone, first shaking to extract, then sealing and centrifuging, and taking the supernatant; preparing a control sample solution; respectively performing GC-MS detection on the control sample solution and the test sample solution, and determining the content of 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in the levocarnitine by an external standard method. The application adopts GC-MS to determine the potential genotoxic impurities 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in levocarnitine, and has high separation efficiency, fast analysis speed and high detection sensitivity, and can effectively control the quality of the levocarnitine.

The invention relates to the technical field of medical instruments, and discloses a composite hyaluronic acid beauty fluid formula, which comprises 2 ml of levocarnitine, 2 ml of furosemide, 2 ml of gastrodin, 1 ml of dexamethasone, 3 ml of triamcinolone acetonide, 1 ml of auxin, 3 ml of lidocaine, and 100 ml of saline water. Through two-way regulation and control, tissue regeneration is not stimulated, the healing property is high, and the problem caused by excessive filling of regenerative materials can be rapidly solved.

The invention relates to a traditional Chinese medicine compound composition for treating oligoasthenospermia and a preparation method thereof. The traditional Chinese medicine compound composition comprises a traditional Chinese medicine component, a western medicine component and an auxiliary material component, the traditional Chinese medicine components comprise the following components: radix astragali, radix ophiopogonis, radix morindae officinalis, herba epimedii, radix polygoni multiflori preparata, semen cuscutae and rhizoma polygonati preparata; the western medicine component is levocarnitine; the auxiliary material components comprise the following components: a zinc-containing component, a selenium-containing component and vitamin E. The traditional Chinese medicine composition contains traditional Chinese medicinal materials such as astragalus membranaceus, radix ophiopogonis and morinda officinalis, Western medicine components and auxiliary material components are cooperatively added, the curative effect on oligoasthenospermia is remarkably improved through the synergistic effect of the multiple components, and the traditional Chinese medicine composition has good market application prospects.

The utility model relates to the technical field of food processing, in particular to an L-carnitine coffee powder semi-finished product deslagging device which comprises a material receiving box, a round hole is formed in the center of the top of the material receiving box, a material receiving frame is installed in the box, and a first supporting frame is fixed to the top of the material receiving box. A motor is fixedly installed at the top of the supporting frame through a supporting plate, an output shaft of the motor is connected with a connecting shaft, and a feeding barrel is slidably installed on the connecting shaft. According to the device, the motor drives the limiting barrel to rotate, and the design of the upper and lower slope rings is utilized, so that the feeding barrel can generate regular up-down vibration, coffee powder can smoothly pass through the screening hopper, large particles and other impurities are effectively removed, the fineness and purity of the coffee powder are improved, meanwhile, the automatic screening process is achieved, manual intervention is reduced, and the screening efficiency is improved. The labor intensity is reduced, and the production efficiency is improved.

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.